Whittle, James R.
The University of Melbourne · Walter and Eliza Hall Institute of Medical Research · Peter MacCallum Cancer Centre
4 papers on CoChatORCID 0000-0002-4740-2037
Most cited papers
- Verified
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 148
- Verified
Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 102
- Verified
Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation
Whittle, J. R., Powell, M. J., Popov, V. M., Shirley, L. A., Wang, C., & Pestell, R. G. (2007) · Trends in Endocrinology & Metabolism
Sirtuins and Resveratrol in MedicineHistone Deacetylase Inhibitors Research
Cited by 51
- Verified
Targeting triple-negative breast cancers with the Smac-mimetic birinapant
Lalaoui, N., Merino, D., Giner, G., Vaillant, F., Chau, D., Liu, L., Kratina, T., Pal, B., Whittle, J. R., Etemadi, N., et al. (2020) · Cell Death & Differentiation
Cell death mechanisms and regulationHistone Deacetylase Inhibitors Research
Cited by 51
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free